In this presentation, we explore why gene therapy must learn from its past to unlock its future. Drawing on decades of experience in viral vector development, the talk examines the growing reliance on high-dose AAV therapies, the safety and commercial challenges this creates, and why potency—not dose—should be the central focus of next-generation gene therapy design. The discussion highlights how capsid engineering, vector design, and manufacturing strategy can be leveraged to build higher-potency therapies, reduce risk, and improve long-term success across the field.
